Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria
The American Journal of Tropical Medicine and Hygiene · 11.01.2023 · 108 (1) · 81-84
DOI: 10.4269/ajtmh.22-0567 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, erschienen am 11.01.2023. Verfasst von Rezika Mohammed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Gondar Hospital, Gondar, Ethiopia. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Malaria, Falciparum, Malaria, Vivax. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
An open label, phase IIa study conducted in Ethiopia evaluated the efficacy, safety, tolerability, and pharmacokinetics of a single 120-mg dose of the phosphatidylinositol 4-kinase inhibitor MMV390048 in Plasmodium vivax malaria. The study was not completed for operational reasons and emerging teratotoxicity data. For the eight adult male patients enrolled, adequate clinical and parasitological response at day 14 (primary endpoint) was 100% (8/8). Asexual parasites and gametocytes were cleared in all patients by 66 and 78 hours postdose, respectively. There were two recurrent P. vivax infections (days 20 and 28) and a new Plasmodium falciparum infection (day 22). MMV390048 exposure in P. vivax patients was lower than previously observed for healthy volunteers. Mild adverse events, mainly headache and gastrointestinal symptoms, were reported by eight patients. Single-dose MMV390048 (120 mg) rapidly cleared asexual parasites and gametocytes in patients with P. vivax malaria and was well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Gondar Hospital, Gondar, Ethiopia.
- Jimma University Clinical Trial Unit, Jimma University Institute of Health, Jimma, Ethiopia.
- Department of Internal Medicine, Jimma University Institute of Health, Jimma, Ethiopia.
- School of Medical Laboratory Sciences, Jimma University Institute of Health, Jimma, Ethiopia.
- HJ-Clinical Trial Consultancy, George, South Africa.
- Medicines for Malaria Venture, Geneva, Switzerland.
Zitieren
APA
Mohammed, R., Asres, M. S., Gudina, E. K., Adissu, W., Johnstone, H., Marrast, A. C., Donini, C., Duparc, S., & Yilma, D. (2023). Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria. The American Journal of Tropical Medicine and Hygiene, 108(1), 81-84. https://doi.org/10.4269/ajtmh.22-0567
Vancouver
Mohammed R, Asres MS, Gudina EK, Adissu W, Johnstone H, Marrast AC, et al. Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria. The American Journal of Tropical Medicine and Hygiene. 2023;108(1):81-84. doi:10.4269/ajtmh.22-0567
BibTeX
@article{Mohammed2023,
author = {Mohammed, Rezika and Asres, Mezgebu Silamsaw and Gudina, Esayas Kebede and Adissu, Wondimagegn and Johnstone, Hilary and Marrast, Anne Claire and Donini, Cristina and Duparc, Stephan and Yilma, Daniel},
title = {Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2023},
volume = {108},
number = {1},
pages = {81--84},
doi = {10.4269/ajtmh.22-0567}
}
EUVIMED